Pancreatic Cancer Treatment: Current Approaches and New Hope for Patients

Table of Contents

• Key Points
• Understanding Pancreatic Cancer
• How Doctors Classify Pancreatic Cancer
• Treatment for Localized Disease
• Pre-Surgery Chemotherapy (Neoadjuvant Treatment)
• Surgical Options
• Post-Surgery Chemotherapy (Adjuvant Treatment)
• Radiation Therapy and New Approaches
• Treatment for Advanced or Metastatic Disease
• Palliative Care and Symptom Management
• Chemotherapy for Metastatic Pancreatic Cancer
• What This Means for Patients
• Limitations and Ongoing Questions
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Pancreatic cancer is classified as resectable, borderline resectable, locally advanced, or metastatic, guiding whether surgery or systemic therapy is used.
• Neoadjuvant chemotherapy before surgery can improve outcomes for borderline resectable and locally advanced disease, with one trial showing 67.4% complete removal.
• After surgery, modified FOLFIRINOX is standard for fit patients, improving median overall survival to 54.4 months versus 35 months with gemcitabine in one trial.
• Palliative care, including endoscopic stenting and nerve blocks, effectively manages symptoms and improves quality of life in advanced pancreatic cancer.

Understanding Pancreatic Cancer

Pancreatic cancer remains one of the most challenging cancers to treat. The most common type is called pancreatic ductal adenocarcinoma (PDAC), which accounts for the majority of pancreatic cancer cases. This cancer is characterized by rapid progression and early spread to other parts of the body.

The numbers tell a sobering story. In 2024, the United States reported 66,440 new cases of pancreatic cancer and 51,750 deaths from the disease. This accounts for 8.6% of all cancer-related deaths. The five-year survival rate from 2014 to 2020 remained low at just 12.8%.

Why is pancreatic cancer so difficult to treat? Several factors contribute to this challenge:

• Late detection: The pancreas is located deep in the abdomen, making early tumors difficult to detect
• Early spread: The pancreas sits near major blood vessels, allowing cancer to invade them quickly
• Limited surgical options: Only 15-20% of patients have tumors that can be surgically removed at diagnosis
• Advanced disease at diagnosis: About 25-30% of patients have locally advanced disease, and 50-60% already have cancer that has spread to distant organs

The development of pancreatic cancer involves a series of genetic changes. Mutations in a gene called KRAS are the most common and occur early in tumor development. These are followed by changes in tumor suppressor genes including CDKN2A, TP53, and SMAD4. These genetic alterations lead to uncontrolled cell growth, resistance to cell death, and the ability to evade the immune system.

Understanding these genetic changes has opened new doors for treatment. Doctors can now develop diagnostic biomarkers (measurable indicators of disease) and create targeted therapies that address specific genetic alterations.

How Doctors Classify Pancreatic Cancer

Doctors classify pancreatic cancer into four main categories based on whether the tumor can be surgically removed. This classification guides treatment decisions.

• Resectable: The tumor does not involve major arteries and has limited contact with veins. These tumors can be removed with upfront surgery followed by chemotherapy after surgery.
• Borderline resectable: The tumor has limited involvement of blood vessels but may be removable if the vessels can be reconstructed. Patients typically receive chemotherapy before surgery.
• Locally advanced: The tumor surrounds major arteries or involves veins that cannot be reconstructed. These tumors are not initially removable, but some may shrink enough with treatment to become operable.
• Metastatic: The cancer has spread to distant organs. Treatment focuses on systemic therapy rather than surgery.

An important distinction exists between locally advanced disease and metastatic disease. Patients with locally advanced cancer may become surgical candidates after receiving chemotherapy, while those with metastatic disease generally are not considered for surgery.

Treatment for Localized Disease

Approximately 15-20% of patients present with localized pancreatic cancer that may be eligible for treatments aimed at curing the disease. For these patients, a multidisciplinary approach involving surgeons, medical oncologists, and radiation oncologists has been shown to improve treatment outcomes and survival.

The treatment strategy for localized disease typically involves a combination of approaches. Surgery remains the primary curative option when possible. However, chemotherapy and sometimes radiation therapy play important roles before or after surgery to improve outcomes.

Pre-Surgery Chemotherapy (Neoadjuvant Treatment)

Neoadjuvant chemotherapy refers to treatment given before surgery. This approach has become increasingly common for borderline resectable and locally advanced pancreatic cancer, with studies showing improved outcomes.

Several important clinical trials have demonstrated benefits of this approach:

• The NUPAT-01 trial tested two chemotherapy regimens in patients with borderline resectable pancreatic cancer. The regimens were FOLFIRINOX (a combination of four drugs: folinic acid, fluorouracil, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel. The trial achieved complete tumor removal with clear margins (called R0 resection) in 67.4% of patients, with a median overall survival of 39.4 months.
• A trial by Jang and colleagues showed that giving chemotherapy before surgery significantly increased the likelihood of removing tumors with clear margins.
• Real-world data from the National Cancer Database showed a survival benefit with neoadjuvant therapy in early-stage (Stage I/II) pancreatic cancer. Median overall survival was 26 months with neoadjuvant therapy compared to 21 months with immediate surgery (hazard ratio = 0.72, p<0.01).

However, not all studies show consistent benefits. A meta-analysis of six randomized controlled trials involving 805 patients with resectable pancreatic cancer found no significant improvement in disease-free or overall survival with neoadjuvant gemcitabine-based chemotherapy or chemoradiation compared to upfront surgery followed by adjuvant therapy. These conflicting findings highlight ongoing uncertainty about the best treatment sequence.

Neoadjuvant therapy offers several advantages. Up to 40-50% of patients may not complete planned chemotherapy after surgery due to complications or decline in function. Starting treatment before surgery ensures more patients receive comprehensive treatment. Additionally, neoadjuvant treatment targets microscopic cancer spread early and provides information about how responsive the tumor is to treatment.

One important finding is that limited tumor shrinkage on imaging does not necessarily mean the treatment is not working. Even when tumors show minimal change on scans, patients may still achieve significant cancer cell death and undergo successful surgery. This highlights the importance of clinical judgment and multidisciplinary reassessment rather than relying solely on imaging.

Surgical Options

Surgery remains the primary curative approach for pancreatic cancer. The type of surgery depends on where the tumor is located in the pancreas.

• Distal pancreatectomy: Used for tumors in the body and tail of the pancreas
• Pancreaticoduodenectomy (Whipple procedure): Performed for tumors in the head or uncinate process of the pancreas

Advances in surgical techniques have improved outcomes for patients. Vascular resection allows surgeons to remove tumors that involve blood vessels. Minimally invasive and robotic-assisted techniques have reduced blood loss and shortened hospital stays in selected patients.

However, recurrence remains a substantial challenge. This is often due to microscopic cancer spread that was already present at diagnosis but not detectable by imaging.

The National Comprehensive Cancer Network (NCCN) classifies tumors based on their involvement with blood vessels. Resectable tumors have no contact or less than 180 degrees of contact with critical vessels. Borderline resectable tumors have limited vascular contact that may allow for reconstruction. Locally advanced tumors have extensive vascular involvement.

The MD Anderson classification system is more inclusive than the NCCN framework. It categorizes some tumors with limited vascular involvement as resectable if reconstruction is feasible. It also expands the borderline resectable category to include tumors with adjacent organ involvement.

The 2017 International Consensus Criteria recommend incorporating biological and conditional factors into treatment decisions. Biological factors include elevated serum CA 19-9 levels, which may suggest microscopic cancer spread. Conditional factors include the patient's performance status and other medical conditions that may affect surgical candidacy.

Post-Surgery Chemotherapy (Adjuvant Treatment)

Even after successful surgery, long-term outcomes for pancreatic cancer remain challenging. Surgery alone yields a five-year survival rate of approximately 20%. This improves to 30-40% with the addition of chemotherapy after surgery.

Adjuvant chemotherapy selection depends primarily on the patient's performance status, which measures how well a patient can perform daily activities.

Patients with good functional capacity (ECOG 0-1) are typically treated with modified FOLFIRINOX. This multiagent regimen includes fluorouracil (5-FU), oxaliplatin, irinotecan, and leucovorin. It offers superior survival benefits compared to other options.

Patients with lower performance status may receive single-agent chemotherapy such as gemcitabine or a fluoropyrimidine. They may also receive gemcitabine combined with capecitabine.

Several landmark trials have established the role of adjuvant chemotherapy:

• The CONKO-001 trial showed that gemcitabine improved median overall survival to 22.8 months compared to 20.2 months with observation after surgery (hazard ratio 0.76; 95% confidence interval, 0.61-0.95; p = 0.01).
• The ESPAC-1 trial demonstrated a survival benefit with 5-FU/leucovorin, increasing median overall survival from 14.0 to 19.7 months (hazard ratio 0.66; 95% confidence interval, 0.52-0.83; p = 0.0005).
• The ESPAC-4 trial reported that gemcitabine combined with capecitabine modestly outperformed gemcitabine alone. Median overall survival improved to 28.0 months compared to 25.5 months (hazard ratio 0.82; 95% confidence interval, 0.68-0.98; p = 0.032).
• The JASPAC 01 trial conducted in Japan compared adjuvant S-1 (an oral chemotherapy drug) versus gemcitabine. After five years, the S-1 group had 44.1% overall survival compared to 24.4% in the gemcitabine group (hazard ratio 0.57; p<0.0001).
• The APACT trial evaluated gemcitabine plus nab-paclitaxel versus gemcitabine alone. A 2021 update revealed improved survival in the combination arm (median overall survival 41.8 versus 37.7 months; p = 0.0091).
• The PRODIGE-24 trial evaluated modified FOLFIRINOX in patients with excellent performance status. This regimen significantly improved median overall survival to 54.4 months compared to 35 months with gemcitabine alone (hazard ratio 0.64; 95% confidence interval, 0.48-0.86; p<0.001). This established modified FOLFIRINOX as the current standard for fit patients.

A small phase II study of 22 patients tested gemcitabine combined with cisplatin. This combination achieved a median overall survival of 35.5 months. However, significant toxicity occurred, with grade 3 or 4 adverse events reported in nearly 59% of patients, limiting its broader use.

Radiation Therapy and New Approaches

The role of radiation therapy in pancreatic cancer treatment remains debated. Its optimal use is still under clinical investigation.

Neoadjuvant chemoradiation (chemotherapy combined with radiation before surgery) has shown potential benefits in certain settings. The PREOPANC trial demonstrated improved overall survival with gemcitabine-based neoadjuvant chemoradiotherapy compared to upfront surgery. This benefited both resectable and borderline resectable pancreatic cancer patients.

The ESPAC-5F phase II trial reported higher one-year survival with chemoradiation, supporting its use in selected patients.

However, more recent evidence has raised questions about routine use of radiation. The ALLIANCE A021501 trial compared modified FOLFIRINOX alone versus modified FOLFIRINOX followed by hypofractionated radiotherapy in borderline resectable pancreatic cancer. The addition of radiation did not provide a survival advantage.

Additional evidence comes from a retrospective multicenter study by Macedo and colleagues. This study evaluated neoadjuvant FOLFIRINOX versus gemcitabine/nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer. Patients who achieved a 50% or greater decline in CA 19-9 levels experienced significantly improved overall survival, with a median overall survival of 42.3 months. The pathologic response correlated with survival outcomes.

The NEONAX trial explored perioperative versus adjuvant gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer. Although the primary endpoint was not met, the trial reported longer median disease-free survival and overall survival in the perioperative group.

Some trials have shown limited benefit from radiation. The ESPAC-1 trial raised concerns about adjuvant radiation, showing worse outcomes with combined 5-FU-based chemotherapy in the postoperative setting. The LAP-07 trial in locally advanced, unresectable pancreatic cancer found no survival benefit from adding capecitabine-based chemoradiation after gemcitabine therapy.

Chemoradiation may be selectively used after an R1 resection (when cancer cells are found at the edge of removed tissue) or as part of neoadjuvant therapy in borderline resectable or locally advanced pancreatic cancer. The SWOG trial showed no added benefit from combining radiation with FOLFIRINOX, and its use in the neoadjuvant setting is not currently recommended.

Carbon ion radiotherapy (CIRT) has emerged as a novel treatment for patients with locally advanced unresectable pancreatic cancer. This is particularly relevant for patients who do not respond to or cannot tolerate conventional X-ray radiation.

A prospective study by Okamoto and colleagues examined CIRT alone and in combination with chemotherapy in 44 patients with unresectable pancreatic cancer. Most patients had received prior neoadjuvant chemotherapy. Results showed:

• Median overall survival of 29.6 months with CIRT
• Median overall survival of 34.5 months from initiation of initial chemotherapy
• Two-year overall survival rate of 56.6%
• Two-year local control rate of 76.1%
• Two-year progression-free survival rate of 29.0%

A multicenter retrospective study in Japan by Kawashiro and colleagues reviewed 72 patients treated with CIRT for locally advanced pancreatic cancer. This study reported a two-year overall survival rate of 46% and median survival of 21.5 months, with a cumulative two-year local recurrence rate of 24%.

Another study by Liermann and colleagues reported high local control rates of 89% at one year following CIRT with or without concurrent gemcitabine in 21 patients. However, this study did not demonstrate clear improvement in overall survival (median 11.9 months). The authors attributed this to the aggressive nature of the disease, particularly in patients who progressed after prior chemotherapy and developed early distant metastases.

Treatment for Advanced or Metastatic Disease

The management of unresectable or metastatic pancreatic cancer requires a multidisciplinary approach tailored to the extent of disease, symptoms, and patient performance status.

Advanced pancreatic cancer follows either local extension or systemic spread, both contributing to illness and death. Notably, up to one-third of patients die from local disease progression without evidence of distant metastasis. Systemic therapy remains the primary treatment, supported by local interventions for symptom relief and quality of life improvement.

Palliative Care and Symptom Management

Palliative care focuses on relieving symptoms and improving quality of life for patients with advanced pancreatic cancer. Several approaches are available.

Endoscopic ultrasound (EUS)-guided interventions are increasingly used for palliative decompression (relieving blockages). EUS-guided biliary drainage has emerged as a viable alternative when standard endoscopic procedures fail or are anatomically challenging. This technique is associated with high technical success and favorable safety profiles in expert centers.

EUS-guided gastrojejunostomy provides a minimally invasive option for patients with malignant gastric outlet obstruction (blockage preventing food from leaving the stomach). This offers comparable symptom relief to surgical bypass with shorter recovery time.

Stent choice depends on prognosis:

• Plastic stents are suitable for patients with life expectancy less than 6 months
• Self-expanding metal stents (SEMS) offer longer patency for patients with better prognosis

For duodenal obstruction, endoscopic stenting provides rapid symptom relief in frail patients. Surgical gastrojejunostomy is preferred for patients with good performance status or those with both biliary and duodenal obstruction.

Pain management is critical in advanced pancreatic cancer. For patients with refractory pain, endoscopic or percutaneous celiac plexus neurolysis and thoracoscopic splanchnicectomy are effective options to reduce opioid requirements. These interventions should be tailored based on symptom severity, prognosis, and patient preferences.

EUS-guided locoregional therapies are gaining traction. EUS-guided fine-needle injection enables local delivery of therapeutic agents directly into the tumor, including chemotherapy, gene therapy vectors, or immunomodulators. This approach aims to increase local efficacy while minimizing systemic toxicity.

EUS-guided radiofrequency ablation has emerged as a minimally invasive technique for destroying pancreatic tumors. This technique uses a specialized electrode probe to deliver thermal energy under real-time ultrasound guidance, leading to localized tumor death. Early-phase studies suggest this may improve local control and potentially work together with systemic treatments.

Chemotherapy for Metastatic Pancreatic Cancer

Systemic therapy is the cornerstone of treatment for metastatic pancreatic cancer. Multiagent regimens outperform single-agent chemotherapy.

FOLFIRINOX offers the greatest survival benefit, extending median overall survival to 11.1 months compared to 6.8 months with gemcitabine alone.

The MPACT trial established gemcitabine plus nab-paclitaxel as an effective alternative, particularly in high-burden disease. This combination achieved median overall survival of 8.5 months with long-term survival reported in select patients.

Other gemcitabine-based combinations, including those with 5-FU, erlotinib, cisplatin, or capecitabine, have shown limited or inconsistent survival benefits.

The FIRGEM regimen, combining fixed-dose gemcitabine with irinotecan and FOLFIRI.3, improved progression-free survival to 6 months compared to 3.4 months with gemcitabine alone. However, this was associated with increased hematologic toxicity (blood-related side effects).

The NAPOLI-3 trial established Nalirifox (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) as a frontline option. This regimen showed improvement over gemcitabine/nab-paclitaxel (11.1 versus 9.2 months; hazard ratio = 0.83; p = 0.04). Nalirifox had more gastrointestinal side effects but fewer hematologic events.

A meta-analysis of over 2,500 patients across seven phase III trials confirmed longer progression-free survival with Nalirifox and FOLFIRINOX (7.4 and 7.3 months, respectively) compared to gemcitabine/nab-paclitaxel (5.7 months). Overall survival was also higher for Nalirifox (11.1 months) compared to gemcitabine/nab-paclitaxel (10.4 months), although not significantly different from FOLFIRINOX.

What This Means for Patients

The treatment landscape for pancreatic cancer has evolved significantly. Several key points are important for patients to understand.

First, treatment is highly individualized. The best approach depends on the stage of disease, the tumor's genetic characteristics, and the patient's overall health and performance status.

Second, multidisciplinary care matters. Patients treated by teams including surgeons, medical oncologists, radiation oncologists, and palliative care specialists tend to have better outcomes.

Third, clinical trials offer access to promising new treatments. Many of the advances described in this review came from patients participating in clinical trials.

Fourth, even when cure is not possible, treatments can extend survival and improve quality of life. Palliative care interventions can effectively manage symptoms including pain, obstruction, and nutritional problems.

Limitations and Ongoing Questions

Despite advances, several important questions remain unanswered.

The optimal treatment sequence for resectable pancreatic cancer is still debated. Some studies show benefits from neoadjuvant therapy, while others do not. Better methods are needed to identify which patients will benefit most from treatment before surgery.

The role of radiation therapy remains unclear. While some studies show benefits in specific situations, others show no advantage. More research is needed to identify which patients might benefit from radiation.

Pancreatic cancer has traditionally been resistant to immunotherapy (treatments that help the immune system fight cancer). The dense, immunosuppressive environment around pancreatic tumors makes it difficult for immune therapies to work. New approaches are needed to overcome this barrier.

Recurrence after surgery remains common. Even with the best available treatments, many patients experience cancer returning. Better understanding of microscopic disease spread and new treatments to prevent recurrence are needed.

Recommendations for Patients

Based on this comprehensive review, several recommendations emerge for patients with pancreatic cancer:

1. Multidisciplinary care matters in localized disease. A multidisciplinary approach involving surgical, medical, and radiation oncology expertise has been shown to improve treatment outcomes and survival.
2. Discuss clinical trial options. Many promising treatments are available through clinical trials. Ask your oncologist whether any trials might be appropriate for your situation.
3. Understand your treatment goals. Discuss with your care team whether the goal is cure, extending survival, or improving quality of life. This helps guide treatment decisions.
4. Consider genetic testing. Testing for genetic mutations can identify targeted therapy options and inform treatment decisions.
5. Address symptoms proactively. Do not wait for symptoms to become severe. Palliative care can help manage pain, nausea, obstruction, and other problems throughout treatment.
6. Maintain nutrition and strength. Pancreatic cancer and its treatment can affect nutrition and physical function. Work with dietitians and rehabilitation specialists to maintain your strength.
7. Build a support network. Pancreatic cancer treatment is demanding. Support from family, friends, support groups, and mental health professionals can help you cope with the challenges.

Frequently Asked Questions

What are the stages of pancreatic cancer and how do they affect treatment?

Doctors classify pancreatic cancer into four groups based on whether the tumor can be surgically removed: resectable, borderline resectable, locally advanced, and metastatic. Resectable tumors can be removed upfront, while borderline and locally advanced tumors often receive chemotherapy first. Metastatic cancer has spread to distant organs, so treatment focuses on systemic therapy rather than surgery.

What is neoadjuvant chemotherapy and why is it used before surgery?

Neoadjuvant chemotherapy is given before surgery. It is increasingly used for borderline resectable and locally advanced pancreatic cancer. One trial found that 67.4% of patients achieved complete tumor removal with clear margins, with a median overall survival of 39.4 months. Starting treatment before surgery ensures more patients receive comprehensive treatment, since up to 40-50% may not complete chemotherapy after surgery.

What chemotherapy options are available after surgery for pancreatic cancer?

After surgery, chemotherapy choice depends on your performance status. Patients with good functional capacity (ECOG 0-1) typically receive modified FOLFIRINOX, which in one trial improved median overall survival to 54.4 months compared to 35 months with gemcitabine alone. Those with lower performance status may receive single-agent gemcitabine or a fluoropyrimidine, or gemcitabine combined with capecitabine.

What is the role of radiation therapy in pancreatic cancer treatment?

The role of radiation therapy remains debated. Some trials, like PREOPANC, showed improved overall survival with neoadjuvant chemoradiotherapy, while others, such as ALLIANCE A021501, found no survival advantage when radiation was added to modified FOLFIRINOX. Chemoradiation may be selectively used after an R1 resection or as part of neoadjuvant therapy in borderline resectable or locally advanced disease.

What chemotherapy regimens are used for metastatic pancreatic cancer?

For metastatic pancreatic cancer, multiagent regimens are preferred. FOLFIRINOX extended median overall survival to 11.1 months compared to 6.8 months with gemcitabine alone. Gemcitabine plus nab-paclitaxel achieved 8.5 months. The NAPOLI-3 trial established Nalirifox as a frontline option, showing 11.1 months versus 9.2 months for gemcitabine/nab-paclitaxel, with more gastrointestinal but fewer hematologic side effects.

What palliative care options are available for advanced pancreatic cancer?

Palliative care focuses on relieving symptoms and improving quality of life. Options include endoscopic ultrasound-guided biliary drainage for blockages, gastrojejunostomy for gastric outlet obstruction, and celiac plexus neurolysis for refractory pain. Stent choice depends on prognosis: plastic stents for life expectancy less than 6 months, and self-expanding metal stents for longer patency. These interventions aim to reduce opioid requirements and manage symptoms.

When should a patient with pancreatic cancer seek a second opinion about treatment?

A second opinion is worth considering when the treatment sequence is unclear, since the optimal approach for resectable pancreatic cancer is still debated and studies disagree on whether chemotherapy before surgery helps. It also helps when radiation is proposed, because its role remains under investigation and some trials show no survival advantage. Because treatment depends on stage, tumor genetics, and performance status, an independent review can clarify whether surgery, neoadjuvant chemotherapy, or another option fits. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies.

Journal: International journal of molecular sciences

License: CC BY (open access)

Authors: Supriya Peshin, Ehab Takrori, Naga Anvesh Kodali, Faizan Bashir, and Sakshi Singal

Author Affiliations:

• Department of Internal Medicine, Norton Community Hospital, Norton, VA, USA
• College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
• Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA
• School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
• Department of Hematology & Oncology, East Tennessee State University, Johnson City, TN, USA

Publication: International Journal of Molecular Sciences, 2025, Volume 26, Article 7055

Publication Date: July 22, 2025

DOI: https://doi.org/10.3390/ijms26157055

This patient-friendly article is based on peer-reviewed research. The information presented here is for educational purposes and should not replace consultation with qualified healthcare providers. Patients should discuss their individual treatment options with their medical team.